Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03758781
Title IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

lung non-small cell carcinoma

melanoma

transitional cell carcinoma

head and neck squamous cell carcinoma

renal cell carcinoma

Therapies

Cyclophosphamide + IRX-2 + Nivolumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
H Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field